Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue
Publishing timestamp: 2024-02-06 12:17:42
Summary
Eli Lilly reported fourth-quarter revenue and adjusted earnings that exceeded expectations. The strong launch of their weight loss drug, Zepbound, and higher prices for their diabetes treatment, Mounjaro, contributed to the positive results. However, there were mentions of stock falling and lower sales for other products. Eli Lilly also issued its full-year forecast for 2024, which was generally in line with expectations. The company expects revenue growth to accelerate in the second half of the year.
Sentiment: MIXED
Tickers: LLY,
Keywords: breaking news, biotechnology, earnings, pharmaceuticals, health care industry, eli lilly and co, business news, business, biotech and pharmaceuticals,
Source: https://www.cnbc.com/2024/02/06/eli-lilly-lly-earnings-q4-2023.html